Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
5 and 10 mg Donepezil as well as 4 and 8 mg Ondansetron are under final development using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
New Active Ingredient + Innovative Drug Delivery System = Business Success More
A liquid system which enables rapid transmigration of therapeutic doses of up to large molecules More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
The XGEL ™ polymer technology is available for licensing and replaces the need to use animal-derived gelatine in pharmaceutical and healthcare products More
Own patented delivery system for the release over 1 and 3 months formulations of leuprolide, triptorelin and goserelin More
Antroquinonol® is a non-toxic, highly effective cancer treatment agent, developed using natural organic chemistry. More
4 and 8 mg Ondansetron are under final development using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
Your selection
Browse By
- Industry sector
- Intravesical
- Nasal
- Nasal topical
- Ophthalmic
- Oral liquid
- Oral solid
- Otic
- Parenteral
- Pulmonary
- Rectal
- Systemic
- Topical
- Vaginal
- Therapeutic target
- Anti-oxidant
- Bladder cancer
- Bone cancer
- Brain cancer
- Breast cancer
- Cancer (other)
- Cancer side effects
- Cervical cancer
- Colorectal cancer
- Head and neck cancer
- Kaposi's sarcoma
- Kidney cancer
- Leukemia
- Liver cancer
- Lung cancer
- Lymphoma
- Ovarian cancer
- Pancreatic cancer
- Polyps
- Prostate cancer
- Skin cancer
- Stomach/Esophageal
- Testicular cancer
- Transplant
- Treatments
- Tumor (other)
- Vaginal Cancer
- Womb cancer
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us